Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (MGN-3)

International Journal of Immunotherapy

Volumn 14, Issue 2, 1998, Pages 89-99

  Ghoneum, M ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ARABINOXYLANE; CHROMIUM 51; IMMUNOMODULATING AGENT; MGN 3; PLANT EXTRACT; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAN; CELL ACTIVITY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; LYMPHOCYTE CULTURE; MALE; NATURAL KILLER CELL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; RAJI CELL; RICE; TUMOR CELL;

EID: 0031861169     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ghoneum M., Ghonaim M., Namatalla G., et al. Natural killer cell activity in hepatocellular carcinoma and its relation to the etiology of the disease. J. Clean Technol, Environ. Toxicol. & Occup. Med., 5, 267, 1996.
2. Ghoneum M., Jackson K., Salem F., Gill G. Murine intersex difference in methylcholanthrene-induced tumor and its correlation with NK activity. Int. J. lmmunopathol. Pharmacol., 4, 9, 1991.
3. Ghoneum M., Salem R, Gill G., Jackson K., Betru Y., Allen H. Natural killer cell activity and tumor development of age-related variation to 3-methylcholanthrene. In: Ades Edwin W., Lopes C. (Eds.). "Natural Killer Cells and Host Defense" Base:Karger, New York, 1989, pp 278-284.
4. Herberman R.B. Possible role of NK cells in host resistance against tumors and diseases. Clin. Immun. Allergy, 3, 479, 1983.
5. Roder J.C., Pross H.F. The biology of human NK cells. J. Clin. Immun., 2, 249, 1983.
6. Klein M., Roder J., Haliotis T., et al. Chediak-Higashi gene in humans: II. The selectivity of the defect in NK and antibody-dependent cell-mediated cytotoxity function. J. Exp. Med., 151, 1049, 1980
7. Roder J.C., Haliotis T., Klein M., et al. A new immunodeficiency disorder in humans involving NK cells. Nature, 284, 553, 1980.
8. Roder J.C., Duwe A.K. The beige mutation in the mouse selectively impairs NK cell function. Nature, 278, 451, 1979.
9. Talmadge J E., Meyers K.M., Prieur DJ., Starkey J.R. Role of NK cells in tumor growth and metastasis in beige mice. Nature, 284, 622, 1980.
10. Warner J.F., Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumor development and metastasis in vivo. Nature, 300, 31, 1982
11. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of NK-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155, 1823, 1982.
12. Lotzova E., Savary C.A., Herberman R.B. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2 J. Immunol , 138, 2718, 1987.
13. Rosenberg S.A. Lymphokine-activated killer cells: a new approach to the immunotherapy of cancer (editorial). J. Natl. Cancer lnst., 75, 595, 1985.
14. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observation on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer N. Eng. J. Med., 313, 1485, 1985.
15. Rosenberg S.A., Lotze M.T., Muul L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone N. Eng J. Med., 316, 889, 1987
16. Fisher R.I., Coltman C.A., Doroshaw J.H., et al Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann. Intern. Med., 108, 518, 1988.
17. Whiteside T.L., Bryant J., Day R., Herberman R.B. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J. Clin. Lab. Analysis, 4, 102, 1990.
18. Fletcher M.A., Baron G.G., Ashman M., Fischi M.A., Klimas N.G. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn. Clin, Immunol., 5, 69, 1987.
19. Kumagai K., Itoh K., Suzuki R., Hinuma S., Saitoh F. Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. J. Immunol., 129, 388, 1982.
20. Ghoneum M., Jewitt A. (manuscript in preparation).
21. Herberman R.B., Ortaldo J.R., Djeu J.Y., et al. Role of interferon in regulation of cytotoxicity by NK cells and macrophages. Ann. N.Y. Acad. Sci., 350, 63, 1980.
22. Djeu J.Y. Antibody-dependent cell-mediated cytotoxicity and NK cell phenomenon. J. Am. Vet Med. Assoc., 181, 1043, 1982.
23. Djeu J.Y. Production of interferon by NK cells. Clin. Immun. Allergy, 3, 561, 1983.
24. Roder J.C., Kiessling R., Biberfeld P., Anderson B. Target-effector interaction in the natural (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol., 121. 2509, 1978
25. Ghoneum M., Gill G , Wojdani A., Payne C., Alfred L. Suppression of basal and Corynebactenum parvum-augmented NK activity during chemically induced tumor development Int. J. Immunopharm., 9, 71, 1987.
26. Lichtenstein A., Bick A, Cantrell J., Zignelboim J. Augmentation of NK activity by Corynebacterium parvum fractions in vivo and in vitro. Int. J. Immunopharmac., 5, 137, 1983.
27. Wolfe S.A , Tracy D E., Hanny C S. Induction of NK cells by BCG. Nature, 262, 584, 1976.
28. Sharma B., Odom L.F Generation of killer lymphocytes in vitro against human autologous leukemia cells with soluble bacterial extracts. Cancer Immunol. Immunother., 7, 93, 1979.
29. Maddox D.E., Shibata S., Goldstein I.J Stimulated macrophages express a new glycoprotein receptor reactive with Griffonia simplicitolia 1-ß4 isolectin. Proc. Natl. Acad. Sci. USA., 79, 166, 1982.
30. Cunnick J.E., Sakamoto K., Chapes S.K., Fortner G.W., Takemoto D.J. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Morodica charantia). Cell. Immunol., 126, 278, 1990.
31. Chihara G., Hamuro J., Maeda Y.Y, Aria Y, Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentman, from Lentinus edodes (Berk) Sing (an edible mushroom). Cancer Res., 30, 2776, 1970.
32. Herberman R.B., Nunn-Hargrove M.E Augmentation of NK (NK) cell activity by lentinan. In: Aoki T., Urushizaki I., Tsubura E. (Eds.). "Manipulation of Host Defense Mechanisms". Excerpta Medica, Princeton, NJ, 1981, pp 188-198.
33. Miyakoshi H., Aoki T., Usuda Y. Immunopotentiation activity of lentinan. In: Aoki T., Urushizaki I., Tsubura E. (Eds.). "Manipulation of Host Defense Mechanisms". Excerpta Medica, Princeton, NJ, 1981, pp 118-126.
34. Miyakoshi H , Aoki T. Acting mechanisms of lentinan on human-11 enhancement on non-specific cell-mediated cytotoxicity as an interferon inducer. Int. J Immunopharmac., 6, 373, 1984.
35. Taguchi T., Furue H., Mazima H. Phase II study of lentinan gan to kagakuryoho. Cancer Chemotherapy, 8, 422, 1981.
36. Takeo S., Kado H., Yamamoto H., et al. Studies on an antitumor polysacchande RBS derived from rice bran. II. Preparation and general properties of RON, an active fraction of RBS. Chem. Pharm. Bull., 36, 3609, 1988.
37. Takenaka S. Hemicellulose in rice bran fibre reduces thymus atrophy in rats treated with bis (tri-normal-butyltin) oxide. Chemosphere, 25, 327, 1992.
38. Tsuji H., Nomiyama K , Ikeda K., et al. Effects of rice bran fiber and cholestyramine on peripheral blood cells and biochemical parameters in Yusho. Fukuoka Igaku Zasshi. Fukuoka Acta Medica, 82, 330, 1991.
39. Ghoneum M., Namatalla G Natural killer immunomodulatory function in 27 cancer patients by MGN-3, a modified arabinoxylane from rice bran. Abstract, 87th Ann. Meeting Am. Assoc. Can Res.. April 20-4 1996, Washington, D.C.
40. Ghoneum M Immunomodulatory and anti-cancer properties of (MGN-3), a modified xylose from rice bran, in 5 patients with breast cancer Abstract, Ann. Am Assoc. Can Res. (AACR) special conference: "The Interference Between Basic and Applied Research " November 5-8 1995. Baltimore, M D.